Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Ajit, Ahuja, Vineet, Midha, Vandana, Sinha, Saroj Kant, Pai, C. Ganesh, Kedia, Saurabh, Mehta, Varun, Bopanna, Sawan, Abraham, Philip, Banerjee, Rupa, Bhatia, Shobna, Chakravartty, Karmabir, Dadhich, Sunil, Desai, Devendra, Dwivedi, Manisha, Goswami, Bhabhadev, Kaur, Kirandeep, Khosla, Rajeev, Kumar, Ajay, Mahajan, Ramit, Misra, S. P., Peddi, Kiran, Singh, Shivaram Prasad, Singh, Arshdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609395/
https://www.ncbi.nlm.nih.gov/pubmed/32646198
http://dx.doi.org/10.5217/ir.2019.09176
_version_ 1783605024376487936
author Sood, Ajit
Ahuja, Vineet
Midha, Vandana
Sinha, Saroj Kant
Pai, C. Ganesh
Kedia, Saurabh
Mehta, Varun
Bopanna, Sawan
Abraham, Philip
Banerjee, Rupa
Bhatia, Shobna
Chakravartty, Karmabir
Dadhich, Sunil
Desai, Devendra
Dwivedi, Manisha
Goswami, Bhabhadev
Kaur, Kirandeep
Khosla, Rajeev
Kumar, Ajay
Mahajan, Ramit
Misra, S. P.
Peddi, Kiran
Singh, Shivaram Prasad
Singh, Arshdeep
author_facet Sood, Ajit
Ahuja, Vineet
Midha, Vandana
Sinha, Saroj Kant
Pai, C. Ganesh
Kedia, Saurabh
Mehta, Varun
Bopanna, Sawan
Abraham, Philip
Banerjee, Rupa
Bhatia, Shobna
Chakravartty, Karmabir
Dadhich, Sunil
Desai, Devendra
Dwivedi, Manisha
Goswami, Bhabhadev
Kaur, Kirandeep
Khosla, Rajeev
Kumar, Ajay
Mahajan, Ramit
Misra, S. P.
Peddi, Kiran
Singh, Shivaram Prasad
Singh, Arshdeep
author_sort Sood, Ajit
collection PubMed
description Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
format Online
Article
Text
id pubmed-7609395
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Association for the Study of Intestinal Diseases
record_format MEDLINE/PubMed
spelling pubmed-76093952020-11-10 Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease Sood, Ajit Ahuja, Vineet Midha, Vandana Sinha, Saroj Kant Pai, C. Ganesh Kedia, Saurabh Mehta, Varun Bopanna, Sawan Abraham, Philip Banerjee, Rupa Bhatia, Shobna Chakravartty, Karmabir Dadhich, Sunil Desai, Devendra Dwivedi, Manisha Goswami, Bhabhadev Kaur, Kirandeep Khosla, Rajeev Kumar, Ajay Mahajan, Ramit Misra, S. P. Peddi, Kiran Singh, Shivaram Prasad Singh, Arshdeep Intest Res Review Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. Korean Association for the Study of Intestinal Diseases 2020-10 2020-07-13 /pmc/articles/PMC7609395/ /pubmed/32646198 http://dx.doi.org/10.5217/ir.2019.09176 Text en © Copyright 2020. Korean Association for the Study of Intestinal Diseases. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Sood, Ajit
Ahuja, Vineet
Midha, Vandana
Sinha, Saroj Kant
Pai, C. Ganesh
Kedia, Saurabh
Mehta, Varun
Bopanna, Sawan
Abraham, Philip
Banerjee, Rupa
Bhatia, Shobna
Chakravartty, Karmabir
Dadhich, Sunil
Desai, Devendra
Dwivedi, Manisha
Goswami, Bhabhadev
Kaur, Kirandeep
Khosla, Rajeev
Kumar, Ajay
Mahajan, Ramit
Misra, S. P.
Peddi, Kiran
Singh, Shivaram Prasad
Singh, Arshdeep
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title_full Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title_fullStr Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title_full_unstemmed Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title_short Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
title_sort colitis and crohn’s foundation (india) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609395/
https://www.ncbi.nlm.nih.gov/pubmed/32646198
http://dx.doi.org/10.5217/ir.2019.09176
work_keys_str_mv AT soodajit colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT ahujavineet colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT midhavandana colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT sinhasarojkant colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT paicganesh colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT kediasaurabh colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT mehtavarun colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT bopannasawan colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT abrahamphilip colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT banerjeerupa colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT bhatiashobna colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT chakravarttykarmabir colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT dadhichsunil colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT desaidevendra colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT dwivedimanisha colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT goswamibhabhadev colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT kaurkirandeep colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT khoslarajeev colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT kumarajay colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT mahajanramit colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT misrasp colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT peddikiran colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT singhshivaramprasad colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease
AT singharshdeep colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease

Ejemplares similares